Right to Try laws challenge clinical trial process

By CenterWatch
Published: November 2016

Right to Try laws have passed in 32 states. The laws grant patients access to investigational drugs if they have a terminal illness, they’ve considered other options and their doctor will give them a prescription for it. Biopharmaceutical companies can choose to sell the drugs to patients or they can offer the drug for free. The laws purport to make the process faster and easier on patients than the FDA expanded access program; however, the Pharmaceutical Research and Manufacturers of America (PhRMA) would rather see patients gain access to investigational drugs under the oversight of the FDA and IRBs.

To learn more register for our free white paper Right to Try laws challenge clinical trial process.

Please enter in your information below. Fields with an * are required.

Please enter a valid email address to receive an email with a link to download the white paper.   

Please check the types of email communications you would like to receive:

CenterWatch offers a range of white papers for download that investigate and analyze current trends in the clinical trials industry and the impact they have on the research community.

Recent titles from CenterWatch:

eTMF adoption and integration accelerating

Advancing patient protection through proposed Common Rule changes for informed consent

Sites smothered by technology solutions